drugset / Trial / NCT04590586

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

NCT04590586

Phase 3 Completed 515 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.

Timeline

Start
2020-11-24
Primary completion
2021-08-03
Completion
2021-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg Oral
Subject Lanadelumab Monoclonal antibody 300 mg Intravenous
Subject Zilucoplan Peptide 32.4 mg Subcutaneous

Indications